Management of Acute Bronchitis in Healthy Adults

Guideline Recommendations (CHEST 2020)

The CHEST 2020 guideline strongly recommends against routine prescription of any medication (including antibiotics, antivirals, antitussives, inhaled bronchodilators, inhaled or oral corticosteroids, oral NSAIDs, or other agents) for acute bronchitis in otherwise healthy adults because the condition is self‑limited and no drug has shown a clinically significant benefit. Strong recommendation. 1

Antibiotics – should not be prescribed routinely. Strong recommendation. 1
Antivirals – not indicated for acute bronchitis. Strong recommendation. 3
Antitussives – no clinically meaningful benefit; should not be used routinely. Strong recommendation. 3
Inhaled short‑acting β‑agonists – not recommended. Strong recommendation. 3
Inhaled anticholinergics – not recommended. Strong recommendation. 3
Inhaled or oral corticosteroids – not recommended. Strong recommendation. 1
Oral non‑steroidal anti‑inflammatory drugs (NSAIDs) – not recommended for routine use. Strong recommendation. 3

Dipirona (metamizole) – not recommended for acute bronchitis. Strong recommendation. 1
Oral NSAIDs – clinical trials showed they did not significantly reduce cough duration compared with placebo. Moderate‑quality evidence. 5
Dexclorfeniramine – not recommended; antihistamines have no indication in this condition. Strong recommendation. 1

Clinical worsening (beyond persistent symptoms) warrants reassessment and possible antibiotic therapy. Strong recommendation. 3
Strong suspicion of secondary bacterial infection (e.g., new purulent sputum, localized findings) justifies antibiotic use. Strong recommendation. 3
Signs of complications such as fever persisting or recurring, or other indicators of pneumonia, also trigger reconsideration. Strong recommendation. 2

Prescribing antibiotics “just in case” – meta‑analysis of 5,099 patients showed antibiotics reduced cough duration by only 0.46 days on average and increased adverse events (Number Needed to Harm = 24). High‑quality evidence. 5
Routine use of antitussives – multiple trials found no clinically significant benefit. Strong recommendation. 1
Misdiagnosing other airway diseases – up to 65 % of cases labeled as recurrent acute bronchitis are actually mild asthma; clinicians should also consider COPD exacerbation, asthma, and bronchiectasis. Moderate‑quality evidence. 3

Cochrane review (5,099 participants):
- No meaningful difference in overall clinical improvement (Risk Ratio = 1.07; 95 % CI 0.99–1.15). High‑quality evidence. 1
- Increased adverse effects (RR = 1.20; 95 % CI 1.05–1.36). High‑quality evidence. 1
Additional meta‑analysis: minimal cough‑duration benefit of ≈0.5 days, which does not outweigh the risk of antimicrobial resistance. Moderate‑quality evidence. 3